Search

Your search keyword '"A Fucili"' showing total 395 results
Start Over Author "A Fucili"
395 results on '"A Fucili"'

151. LATE-BREAKING ABSTRACT: Risk factors for hospitalization and death in elderly smokers with chronic obstructive pulmonary disease (COPD) and/or chronic heart failure (CHF)

Author

Verduri, Alessia, primary, Beghé, Bianca, additional, Garofalo, Martina, additional, Balduzzi, Sara, additional, Schito, Michela, additional, Ruggieri, Valentina, additional, Fucili, Alessandro, additional, Fabbri, Leonardo M., additional, Clini, Enrico, additional, and Boschetto, Piera, additional

Published
2016
Full Text
View/download PDF

152. Cardiac resynchronization therapy guided by multimodality cardiac imaging

Author

Bertini, Matteo, primary, Mele, Donato, additional, Malagù, Michele, additional, Fiorencis, Andrea, additional, Toselli, Tiziano, additional, Casadei, Francesca, additional, Cannizzaro, Teresa, additional, Fragale, Cristina, additional, Fucili, Alessandro, additional, Campagnolo, Elena, additional, Benea, Giorgio, additional, and Ferrari, Roberto, additional

Published
2016
Full Text
View/download PDF

154. Validation of a self-reported HIV symptoms list: the ISS-HIV symptoms scale

Author

Bucciardini, Raffaella, primary, Pugliese, Katherina, additional, Francisci, Daniela, additional, Costantini, Andrea, additional, Schiaroli, Elisabetta, additional, Cognigni, Miriam, additional, Tontini, Chiara, additional, Lucattini, Stefano, additional, Fucili, Luca, additional, Di Gregorio, Massimiliano, additional, Mirra, Marco, additional, Fragola, Vincenzo, additional, Pompili, Sara, additional, Murri, Rita, additional, and Vella, Stefano, additional

Published
2016
Full Text
View/download PDF

155. Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells

Author

Pannella, Micaela, primary, Caliceti, Cristiana, additional, Fortini, Francesca, additional, Aquila, Giorgio, additional, Vieceli Dalla Sega, Francesco, additional, Pannuti, Antonio, additional, Fortini, Cinzia, additional, Morelli, Marco Bruno, additional, Fucili, Alessandro, additional, Francolini, Gloria, additional, Voltan, Rebecca, additional, Secchiero, Paola, additional, Dinelli, Giovanni, additional, Leoncini, Emanuela, additional, Ferracin, Manuela, additional, Hrelia, Silvana, additional, Miele, Lucio, additional, and Rizzo, Paola, additional

Published
2016
Full Text
View/download PDF

156. HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study

Author

Weimer, L.E., primary, Vinci, M., additional, Borgia, G., additional, Brunetto, M., additional, Sturace, L., additional, Gaeta, G.B., additional, Chemello, L., additional, Buggio, A., additional, Andreone, P., additional, Raimondo, G., additional, Filomia, R., additional, Persico, M., additional, Puoti, M., additional, Rumi, M.G., additional, Benedetti, A., additional, Fargion, S., additional, Ieluzzi, D., additional, Nardone, G., additional, Foti, G., additional, Ciancio, A., additional, Taliani, G., additional, Biliotti, E., additional, Madonia, S., additional, Stagno, B., additional, Alberti, A., additional, Massari, M., additional, Rosina, F., additional, Mazzella, G., additional, Di Leo, A., additional, Iannone, A., additional, Ferrari, C., additional, Orlandini, A., additional, Gragnani, L., additional, Santantonio, T.A., additional, Chessa, L., additional, Erne, E.M., additional, Coppola, C., additional, Andreoni, M., additional, Baldelli, F., additional, Mondelli, M., additional, Blanc, P., additional, Gasbarrini, A., additional, D’Aversa, F., additional, Verucchi, G., additional, Colombo, M., additional, Borghi, M., additional, Craxì, A., additional, Petta, S., additional, Villa, E., additional, Patti, O., additional, Russo, F.P., additional, Strazzabosco, M., additional, Mallano, A., additional, Fucili, L., additional, Massella, M., additional, Kondili, L., additional, Vella, S., additional, and Zignego, A.L., additional

Published
2016
Full Text
View/download PDF

158. In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure

Author

Micaela Pannella, Veronica Tisato, Alessandro Fucili, Rebecca Voltan, Roberto Ferrari, Giorgio Zauli, Paola Rizzo, Paola Secchiero, and Roberto Marci

Subjects
Adult, Chemokine, Article Subject, Angiogenesis, medicine.medical_treatment, Immunology, Proinflammatory cytokine, Pathogenesis, Neovascularization, medicine, Human Umbilical Vein Endothelial Cells, lcsh:Pathology, Humans, Cells, Cultured, Cell Proliferation, Heart Failure, biology, Neovascularization, Pathologic, Cell growth, business.industry, Cell Biology, endothelial cells, cytokines, Middle Aged, Prognosis, Endothelial stem cell, Cytokine, biology.protein, Cytokines, medicine.symptom, Chemokines, business, Research Article, lcsh:RB1-214
Abstract

Although myocardial angiogenesis is thought to play an important role in heart failure (HF), the involvement of circulating proinflammatory and proangiogenic cytokines in the pathogenesis and/or prognosis of HF has not been deeply investigated. By using a highly standardized proliferation assay with human endothelial cells, we first demonstrated that sera from older (mean age52±7.6years;n=46) healthy donors promoted endothelial cell proliferation to a significantly higher extent compared to sera obtained from younger healthy donors (mean age29±8.6years;n=20). The promotion of endothelial cell proliferation was accompanied by high serum levels of several proangiogenic cytokines. When we assessed endothelial cell proliferation in response to HF patients’ sera, we observed that a subset of sera (n=11) promoted cell proliferation to a significantly lesser extent compared to the majority of sera (n=18). Also, in this case, the difference between the patient groups in the ability to induce endothelial cell proliferation correlated to significant (P<0.05) differences in serum proangiogenic cytokine levels. Unexpectedly, HF patients associated to the highest endothelial proliferation index showed the worst prognosis as evaluated in terms of subsequent cardiovascular events in the follow-up, suggesting that high levels of circulating proangiogenic cytokines might be related to a worse prognosis.

Published
2014

159. Acquisition trail: PM Group's CEO Luigi Fucili spoke to Euan Youdale about its acquisition in January by Manitex International and its plans for the Oil & Steel brand

Author

Fucili, Luigi

Subjects
The PM Group -- International economic relations, Advertising agencies -- International economic relations, Construction and materials industries
Abstract

Back in July last year Manitex International announced it would acquire PM Group, which includes Italian articulating crane manufacturer PM and aerial work platform producer Oil & Steel. The deal [...]

Published
2015

160. Alteration of Notch signaling and functionality of adipose tissue derived mesenchymal stem cells in heart failure

Author

Natascha Bergamin, Carlo Alberto Beltrami, Alessandro Fucili, Daniela Cesselli, F. Cecaro, Giorgio Aquila, Antonio Paolo Beltrami, C. Riberti, Roberto Ferrari, Luigi Tavazzi, L. Moretti, Paola Rizzo, Angela Caragnano, and Cinzia Fortini

Subjects
Male, medicine.medical_specialty, Notch signaling pathway, Adipose tissue, Stimulation, NO, Transcription (biology), Internal medicine, medicine, Humans, Notch 2, Aged, Heart Failure, Receptors, Notch, business.industry, Mesenchymal stem cell, Mesenchymal Stem Cells, Middle Aged, medicine.disease, Endocrinology, Adipose Tissue, Heart failure, Female, Stem cell, Cardiology and Cardiovascular Medicine, business, Signal Transduction
Abstract

Circulating mesenchymal cells increase in heart failure (HF) patients and could be used therapeutically. Our aim was to investigate whether HF affects adipose tissue derived mesenchymal cell (adMSC) isolation, functional characteristics and Notch pathway.We compared 25 patients with different degrees of HF (11 NYHA classes I and II and 14 NYHA III and IV) with 10 age and gender matched controls. 100% adMSC cultures were obtained from controls, while only 72.7% and 35.7% from patients with mild or severe HF (p0.0001). adMSC from HF patients showed higher markers of senescence (p16 positive cells: 14±2.3% in controls and 35.6±5.6% (p0.05) and 69±14.7% (p0.01) in mild or severe HF; γ-H2AX positive cells: 3.7±1.2%, 19.4±4.1% (p0.05) and 23.7±3.4% (p0.05) respectively), lower proliferation index (Ki67 positive cells: 21.5±4.9%, 13.2±2.8% and 13.7±3.2%, respectively), reduced pluripotency-associated genes (Oct4 positive cells: 86.7±4.9%, 55±12% (p0.05) and 43.3±8.7% (p0.05), respectively; NANOG positive cells: 89.8±3.7%, 39.6±14.4% (p0.01) and 47±8.1%, respectively), and decreased differentiation markers (α-sarcomeric actin positive cells: 79.8±4.6%, 49±18.1% and 47±12.1% (p0.05) and CD31-positive endothelial cells: 24.5±2.9%, 0.5±0.5% (p0.001) and 2.3±2.3% (p0.001), respectively). AdMSC from HF patients also showed reduced Notch transcriptional activity (lowered expression of Hey 1 and Hey 2 mRNAs). Stimulation with TNF-α of adMSC isolated from controls affected the transcription of several components of the Notch pathway (reduction of Notch 4 and Hes 1 mRNAs and increase of Notch 2 and Hey 1 mRNAs).In HF yield and functionality of adMSC are impaired and their Notch signaling is downregulated.

Published
2013

161. EURObservational Research Programme:regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

Author

Maggioni, A. P., Dahlstrom, U., Filippatos, G., Chioncel, O., Leiro, M. C., Drozdz, J., Fruhwald, F., Gullestad, L., Logeart, D., Fabbri, G., Urso, R., Metra, M., Parissis, J., Persson, H., Ponikowski, P., Rauchhaus, M., Voors, A. A., Nielsen, O. W., Zannad, F., Tavazzi, L., Alonso, A., Ferrari, R., Komajda, M., Wood, D., Manini, M., Taylor, C., Laroche, C., Fiorucci, E., Lucci, D., Gonzini, L., Auer, J., Oberrauner, A., Schumacher, M., Ebner, C., Hallas, A., Espersen, G., Gustafsson, F., Mattsson, N., Egstrup, K., Aagaard, S., Gohr, T., Huld, K., Knudsen, A., Refsgaard, J., Charniot, J., Juillard, A., Pon-Gabrielsen, P., Douna, F., Jondeau, G., Jourdain, P., Michel, L., Hamm, C., Lehinant, S., Rieth, A., Goeing, O., Schultheiss, H. P., Von-Schlippenbach, J., Knollmann, R., Neubuser, C., Katus, H. A., Taeger, T., Zugck, C., Fink, H., Schulz, J., Held, S., Karmann, W., Kreuzer, J., Nitsche, K., Winter, K., Fahnrich, A., Bruederlein, K., Turan, C. H., Berentelg, J., Ittel, T., Rubens, C., Hanke, M., Stoerk, S., Chrysohoou, C., Kaldara, E., Karavidas, A., Margari, R., Matzaraki, V., Nanas, J., Pozios, I., Psarogiannakopoulos, P., Pyrgakis, V., Stefanadis, C., Terrovitis, J., Trikas, A., Xydonas, S., Patrianakos, A., Vardas, P., Douras, A., Nastas, J., Ntertsas, K., Tsaknakis, T., Midi, P., Pajes, G., Moretti, L., Partemi, M., Barberini, F., Branzi, A., Gallelli, I., Grigioni, F., Ionico, T., Pasquale, F., Cas, L., Delmagro, F., Tanghetti, E., Vaccari, A., Mercuro, G., Arcuri, G. M., Marinacci, L., Severini, D., Cosmi, F., Bosi, S., Di Tano, G., Pirelli, S., Fucili, A., Minneci, C., Santoro, G. M., Correale, M., Di Biase, M., Buccolieri, M., Mandorla, S., Martinelli, S., Barbiero, M., Giordano, A., Zanelli, E., Agostoni, P., Fiorentini, C., Salvioni, E., Leuzzi, C., Modena, M. G., Reggianini, L., Cobelli, F., Opasich, C., Baldini, P., Romei, M., Pulitano, G., Ruggeri, A., Bologna, F., Piovaccari, G., Brasolin, B., Fedele, F., Merlo, M., Sinagra, G., Albanese, M. C., Miani, D., Linssen, G., Rodijk, E., Pinto, Y., Van Donk, P., Dunselman, P., Lok, D., Brouwers, F., De Jong, R. M., Boen, R., Hole, T., Rasmussen, L., Christiansen, E. M., Gjertsen, E., Lyng, J., German, M., Hogalmen, G., Skardal, R., Apelland, T., Borgen, M., Forfang, E., Baak, T., Dickstein, K., Olsen, I., Stachurski, D., Juszczyk, Z., Stankala, S., Gilewski, W., Sinkiewicz, W., Kasztelowicz, P., Gabryel, J., Kardaszewicz, P., Lazorko-Piega, M., Bellwon, J., Mosakowska, K., Rynkiewicz, A., Olczyk, S., Pagorek, M., Bartlinski, R., Borej, G., Tarchalski, J., Bartkowiak, R., Sosnowska-Pasiarska, B., Wozakowska-Kaplon, B., Krzeminski, A., Bury, K., Grzegorzko, A., Mirek-Bryniarska, E., Nessler, J., Zabojszcz, M., Broncel, M., Poliwczak, A., Retwinski, A., Soska, K., Grajek, S., Straburzynska-Migaj, E., Kuzniar, J., Rzeszuto, T., Bednarczyk, G., Ruszkowski, P., Piasecka-Krysiak, E., Zambrzycki, J., Nowak, T., Szelemej, R., Balsam, P., Folga, A., Kaplon-Cieslicka, A., Kowalewski, S., Mamcarz, A., Marchel, M., Opolski, G., Welnicki, M., Jankowska, E., Nowak, J., Nowalany-Kozielska, E., Rozentryt, P., Zembala, M., Kleinrok, A., Prokop-Lewicka, G., Kudlinska, B., Radoi, M., Macarie, C., Vinereanu, D., Capalneanu, R., Giuca, A., Ionescu, D. D., Nechita, E., Datcu, M., Istrate, C., Vladoianu, M., Christodorescu, R., Salguero, R., Blanco, V. M., Lavilla, M. A., Comin-Colet, J., Cantillo, D., Bernal, J., del Prado, J. M., Pita, A., Aguero, J., Jimenez, J. F., Calvo, F., Gonzalez, R., Molina, B., Luengos, D., Lostal, C., Bonet, L., Gonzalez, P., Soriano, F., Campos, M. J., Karlstrom, P., Nyrinder, I., Olsson, B., Pettersson, T., Stenberg, A., Lindmark, K., Asserlund, B., Faculteit Medische Wetenschappen/UMCG, Cardiovascular Centre (CVC), ACS - Amsterdam Cardiovascular Sciences, Cardiology, Maggioni, Aldo P, Dahlström, Ulf, Filippatos, Gerasimo, Chioncel, Ovidiu, Leiro, Marisa Crespo, Drozdz, Jaroslaw, Fruhwald, Friedrich, Gullestad, Lar, Logeart, Damien, Fabbri, Gianna, Urso, Renato, Metra, Marco, Parissis, John, Persson, Han, Ponikowski, Piotr, Rauchhaus, Mathia, Voors, Adriaan A., Nielsen, Olav Wendelboe, Zannad, Faiez, Tavazzi, Luigi, on behalf of the Heart Failure Association of the European Society of Cardiology (HFA): [.., F. Barberini, A. Branzi, I. Gallelli, F. Grigioni, T. Ionico, F. Pasquale, and ]

Subjects
Registrie, Male, Time Factors, Peripartum cardiomyopathy, Pilot Projects, Cardiovascular Agents/therapeutic use, Acute heart failure, Chronic heart failure, Observational studies, Pharmacological treatments, Prognosis, Aged, Cardiovascular Agents, Europe, Female, Follow-Up Studies, Heart Failure, Hospital Mortality, Hospitalization, Humans, Middle Aged, Prospective Studies, Inpatients, Registries, GUIDELINES, CLINICAL CHARACTERISTICS, Medicine, Prospective cohort study, POPULATION, Hospital Mortality/trends, education.field_of_study, OUTCOMES, Ejection fraction, Mortality rate, HOSPITALIZATION, Inpatient, Cardiology and Cardiovascular Medicine, Pharmacological treatment, Human, medicine.medical_specialty, acute heart failure, chronic heart failure, observational studies, pharmacological treatments, prognosis, aged, cardiovascular agents, female, follow-up studies, heart failure, hospital mortality, hospitalization, humans, male, middle aged, pilot projects, prospective studies, time factors, inpatients, registries, cardiology and cardiovascular medicine, EUROPE, Time Factor, Prognosi, Population, DIAGNOSIS, Follow-Up Studie, Europe/epidemiology, ONE-YEAR MORTALITY, Pilot Project, education, Hospitalization/statistics & numerical data, business.industry, medicine.disease, Heart Failure/drug therapy, Observational studie, Prospective Studie, Cardiovascular Agent, Heart failure, REGISTRY, Cardiovascular agent, Emergency medicine, Physical therapy, Observational study, QUALITY-OF-CARE, business
Abstract

AIMS: The ESC-HF Pilot survey was aimed to describe clinical epidemiology and 1-year outcomes of outpatients and inpatients with heart failure (HF). The pilot phase was also specifically aimed at validating structure, performance, and quality of the data set for continuing the survey into a permanent Registry.METHODS: The ESC-HF Pilot study is a prospective, multicentre, observational survey conducted in 136 Cardiology Centres in 12 European countries selected to represent the different health systems across Europe. All outpatients with HF and patients admitted for acute HF on 1 day per week for eight consecutive months were included. From October 2009 to May 2010, 5118 patients were included: 1892 (37%) admitted for acute HF and 3226 (63%) patients with chronic HF. The all-cause mortality rate at 1 year was 17.4% in acute HF and 7.2% in chronic stable HF. One-year hospitalization rates were 43.9% and 31.9%, respectively, in hospitalized acute and chronic HF patients. Major regional differences in 1-year mortality were observed that could be explained by differences in characteristics and treatment of the patients.CONCLUSION: The ESC-HF Pilot survey confirmed that acute HF is still associated with a very poor medium-term prognosis, while the widespread adoption of evidence-based treatments in patients with chronic HF seems to have improved their outcome profile. Differences across countries may be due to different local medical practice as well to differences in healthcare systems. This pilot study also offered the opportunity to refine the organizational structure for a long-term extended European network.

Published
2013
Full Text
View/download PDF

162. Growth and economic performance of kid production under different rearing systems and slaughter ages in arid areas of Argentina

Author

Juan Carlos Guevara, M. Fucili, S. Paez Lama, Vanina Egea, Liliana Inés Allegretti, and Diego Grilli

Subjects
ECONOMIC PERFORMANCE, REARING SYSTEM, Ciencias Veterinarias, Artificial rearing, Biology, Animal science, Food Animals, Ground corn, CIENCIAS AGRÍCOLAS, Otras Ciencias Veterinarias, Alfalfa hay, Criollo tobacco, Weaning, Animal Science and Zoology, KIDS GROWTH
Abstract

This paper evaluated the growth performance of Criollo kids under three different rearing systems and determine the economic profit of each rearing systems with slaughter at two different ages. Forty-eight kids were distributed randomly into three groups (n=16). Two groups of kids were naturally reared with their mothers, suckling goat milk until weaning at 30 and 45days of age (groups N30 and N45, respectively). In the remaining group, kids were artificially reared on milk replacer until 45days of age (group A45). Between 30 and 90days, all groups were ad libitum offered with a ration of alfalfa hay and ground corn. Kids from each group were slaughtered at 60 (n=8) and 90 (n=8) days old. The growth performance of kids was acceptable achieving average daily gain (ADG) values ranging between 115.9 and 129.5gd-1, with no major differences between rearing systems at the end of the study. The natural rearing systems showed low values of gross return, which ranged from -0.60 to 5.67US$kid-1, while the artificial rearing system was not economically viable due to the high cost of milk replacer and high demand of labor. The price of milk replacer should not exceed 20% of meat value so that artificial rearing becomes economically feasible. The average gross return of the two natural rearing groups slaughtered at 90days (3.96±1.46US$kid-1) was three times higher than the animals slaughtered at 60days (1.25±0.93US$kid-1). On the basis of the economic results it would be advisable to raise the kids naturally with goat milk and increase the age of slaugther, as long as consumers accept these older animals without decreasing the selling price of meat. Fil: Paez Lama, Sebastián Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Agrarias; Argentina. Universidad "Juan Agustín Maza". Facultad de Ciencias Veterinarias y Ambientales; Argentina Fil: Egea, Angela Vanina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina. Universidad "Juan Agustín Maza". Facultad de Ciencias Veterinarias y Ambientales; Argentina Fil: Grilli, Daniel Guillermo. Universidad "Juan Agustín Maza". Facultad de Ciencias Veterinarias y Ambientales; Argentina Fil: Fucili, Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Allegretti, Liliana Inés. Universidad "Juan Agustín Maza". Facultad de Ciencias Veterinarias y Ambientales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Agrarias; Argentina Fil: Guevara, Juan Carlos. Universidad Nacional de Cuyo. Facultad de Ciencias Agrarias; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina

Published
2013

163. Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study

Author

Chiara Leuzzi, Alberto Papi, Barbara Bottazzi, Mariarita Stendardo, Alessia Verduri, Sara Balduzzi, Claudio Ceconi, Leonardo M. Fabbri, Alberto Mantovani, Alessandro Fucili, Piera Boschetto, and Bianca Beghe

Subjects
Male, Interleukin-1beta, lcsh:Medicine, OBSTRUCTIVE PULMONARY-DISEASE, CHRONIC HEART-FAILURE, CORONARY-ARTERY-DISEASE, VENTRICULAR DYSFUNCTION, CIRCULATING LEVELS, ELDERLY-PATIENTS, CYTOKINES, ASSOCIATION, GUIDELINES, DIAGNOSIS, Systemic inflammation, Coronary artery disease, Pulmonary Disease, Chronic Obstructive, Ventricular Dysfunction, Left, Natriuretic Peptide, Brain, Medicine, Receptors, Interleukin-1 Type II, lcsh:Science, Ultrasonography, COPD, Multidisciplinary, biology, medicine.diagnostic_test, Smoking, Middle Aged, Brain natriuretic peptide, Serum Amyloid P-Component, C-Reactive Protein, Cardiology, Female, medicine.symptom, Research Article, Spirometry, medicine.medical_specialty, Internal medicine, Humans, Aged, Heart Failure, Inflammation, business.industry, lcsh:R, C-reactive protein, Case-control study, medicine.disease, Peptide Fragments, respiratory tract diseases, Heart failure, Case-Control Studies, Chronic Disease, biology.protein, lcsh:Q, business, Biomarkers
Abstract

Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) may coexist in elderly patients with a history of smoking. Low-grade systemic inflammation induced by smoking may represent the link between these 2 conditions. In this study, we investigated left ventricular dysfunction in patients primarily diagnosed with COPD, and nonreversible airflow limitation in patients primarily diagnosed with CHF. The levels of circulating high-sensitive C-reactive protein (Hs-CRP), pentraxin 3 (PTX3), interleukin-1β (IL-1 β), and soluble type II receptor of IL-1 (sIL-1RII) were also measured as markers of systemic inflammation in these 2 cohorts. Patients aged ≥ 50 years and with ≥ 10 pack years of cigarette smoking who presented with a diagnosis of stable COPD (n=70) or stable CHF (n=124) were recruited. All patients underwent echocardiography, N-terminal pro-hormone of brain natriuretic peptide measurements, and post-bronchodilator spirometry. Plasma levels of Hs-CRP, PTX3, IL-1 β, and sIL-1RII were determined by using a sandwich enzyme-linked immuno-sorbent assay in all patients and in 24 healthy smokers (control subjects). Although we were unable to find a single COPD patient with left ventricular dysfunction, we found nonreversible airflow limitation in 34% of patients with CHF. On the other hand, COPD patients had higher plasma levels of Hs-CRP, IL1 β, and sIL-1RII compared with CHF patients and control subjects (p < 0.05). None of the inflammatory biomarkers was different between CHF patients and control subjects. In conclusion, although the COPD patients had no evidence of CHF, up to one third of patients with CHF had airflow limitation, suggesting that routine spirometry is warranted in patients with CHF, whereas echocardiography is not required in well characterized patients with COPD. Only smokers with COPD seem to have evidence of systemic inflammation.

Published
2013

164. Limited occurrence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study

Author

Weimer, L. E., Floridia, M., Bucciardini, R., Baroncelli, S., Galluzzo, C. M., Pirillo, M. F., Fragola, V., Donnini, S., Mirra, M., Di Gragorio, M., Lucattini, S., Fucili, L., Angarano, G., Ladisa, N., Volpe, A., Vullo, V., D’Ettorre, G., Ceccarelli, G., Andreoni, M., Sarmati, L., Delle Rose, D., Tozzi, V., Petrosillo, N., Bellagamba, R., Libertone, R., Cicalini, S., Sighinolfi, L., Segala, D., Armignacco, O., Preziosi, R., Ferrari, C., Degli Antoni, A., Cavalli, A., Parruti, G., Sozio, F., Cosentino, L., Vivarelli, A., Manconi, Pe, Ort, F., Di Martino, M. L., Viale, P., Verucchi, G., Tedeschi, S., Mura, M. S., Mannazzu, M., Cattari, G., Tavio, M., Del Gobbo, R., Mataloni Paggi, A., Giacometti, A., Cirioni, O., Marchionni, E., Silvestri, C., Sebastianelli, S., Brescini, L., Baldelli, F., Francisci, D., Schiaroli, E., Bastianelli, S., Guaraldi, Giovanni, Nardini, Giulia, Stentarelli, Chiara, and Beghetto, Barbara

Subjects
HIV infection, antiretroviral therapy
Published
2013

165. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD

Author

Alessandro Fucili, Carmine Tinelli, Ilaria Campo, Mariarita Stendardo, Claudio Ceconi, Maurizio Luisetti, Leonardo M. Fabbri, Enrico Casimirri, Piera Boschetto, Marina Gorrini, Potena A, Alberto Papi, and Licia Ballerin

Subjects
Glycation End Products, Advanced, Male, medicine.medical_specialty, medicine.drug_class, Clinical Biochemistry, Socio-culturale, Inflammation, Enzyme-Linked Immunosorbent Assay, Biochemistry, Gastroenterology, chronic obstructive pulmonary disease, chemistry.chemical_compound, Pulmonary Disease, Chronic Obstructive, INFLAMMATION, Glycation, Internal medicine, Diabetes mellitus, Natriuretic Peptide, Brain, medicine, Natriuretic peptide, Humans, Advanced glycation end products, chronic heart failure, inflammation, N-terminal pro-brain natriuretic peptide, cardiovascular diseases, Receptor, Aged, Heart Failure, COPD, Lysine, General Medicine, medicine.disease, Peptide Fragments, Endocrinology, chemistry, Heart failure, Case-Control Studies, Chronic Disease, cardiovascular system, Advanced glycation end-product, Female, medicine.symptom, human activities, Biomarkers
Abstract

Background Knowledge of the role of the receptor for advanced glycation end products (RAGE), particularly its soluble form (sRAGE), and of its advanced glycation end product (AGE) ligand, N-(carboxymethyl)lysine adducts (CML), is limited in chronic heart failure (CHF) and in chronic obstructive pulmonary disease (COPD). We evaluated whether the AGE/RAGE system is activated in stable CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical and functional parameters. Materials and methods We measured plasma levels of sRAGE and CML using a sandwich enzyme-linked immunosorbent assay (ELISA) in 143 subjects, aged ≥ 65 years, divided into five groups: 58 with CHF, 23 with COPD, 27 with CHF+COPD and 35 controls (17 healthy smokers and 18 healthy nonsmokers). Individuals with diabetes were excluded from the study. Results Plasma levels of sRAGE and CML were higher in CHF patients than in controls [sRAGE: 0·48 (0·37–0·83) vs. 0·42 (0·29–0·52) ng/mL, P = 0·01; CML: 1·95 (1·58–2·38) vs. 1·68 (1·43–2·00) ng/mL, P = 0·01]. By contrast, sRAGE and CML were not different between both COPD and CHF+COPD patients and controls (P > 0·05). N-terminal pro-brain natriuretic peptide (Nt-pro BNP) correlated with sRAGE, but not with CML, in the patient groups: CHF (r = 0·43, P

Published
2013

166. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

Author

Maggioni, A.P. Dahlström, U. Filippatos, G. Chioncel, O. Leiro, M.C. Drozdz, J. Fruhwald, F. Gullestad, L. Logeart, D. Fabbri, G. Urso, R. Metra, M. Parissis, J. Persson, H. Ponikowski, P. Rauchhaus, M. Voors, A.A. Nielsen, O.W. Zannad, F. Tavazzi, L. Alonso, A. Ferrari, R. Komajda, M. Wood, D. Manini, M. Taylor, C. Laroche, C. Fiorucci, E. Lucci, D. Gonzini, L. Auer, J. Oberrauner, A. Schumacher, M. Ebner, C. Hallas, A. Espersen, G. Gustafsson, F. Mattsson, N. Egstrup, K. Aagaard, S. Gohr, T. Huld, K. Knudsen, A. Refsgaard, J. Charniot, J. Juillard, A. Pon-Gabrielsen, P. Douna, F. Jondeau, G. Jourdain, P. Michel, L. Hamm, C. Lehinant, S. Rieth, A. Goeing, O. Schultheiss, H.P. Von-Schlippenbach, J. Knollmann, R. Neubüser, C. Katus, H.A. Taeger, T. Zugck, C. Fink, H. Schulz, J. Held, S. Karmann, W. Kreuzer, J. Nitsche, K. Winter, K. Fahnrich, A. Bruederlein, K. Turan, C.H. Berentelg, J. Ittel, T. Rubens, C. Hanke, M. Stoerk, S. Chrysohoou, C. Kaldara, E. Karavidas, A. Margari, R. Matzaraki, V. Nanas, J. Pozios, I. Psarogiannakopoulos, P. Pyrgakis, V. Stefanadis, C. Terrovitis, J. Trikas, A. Xydonas, S. Patrianakos, A. Vardas, P. Douras, A. Nastas, J. Ntertsas, K. Tsaknakis, T. Midi, P. Pajes, G. Moretti, L. Partemi, M. Barberini, F. Branzi, A. Gallelli, I. Grigioni, F. Ionico, T. Pasquale, F. Cas, L. Delmagro, F. Tanghetti, E. Vaccari, A. Mercuro, G. Arcuri, G.M. Marinacci, L. Severini, D. Cosmi, F. Bosi, S. Di Tano, G. Pirelli, S. Ferrari, R. Fucili, A. Minneci, C. Santoro, G.M. Correale, M. Di Biase, M. Buccolieri, M. Mandorla, S. Martinelli, S. Barbiero, M. Giordano, A. Zanelli, E. Agostoni, P. Fiorentini, C. Salvioni, E. Leuzzi, C. Modena, M.G. Reggianini, L. Cobelli, F. Opasich, C. Baldini, P. Romei, M. Pulitano, G. Ruggeri, A. Bologna, F. Piovaccari, G. Brasolin, B. Fedele, F. Merlo, M. Sinagra, G. Albanese, M.C. Miani, D. Linssen, G. Rodijk, E. Pinto, Y. Van Donk, P. Dunselman, P. Lok, D. Brouwers, F. De Jong, R.M. Boen, R. Hole, T. Rasmussen, L. Christiansen, E.M. Gjertsen, E. Lyng, J. German, M. Hogalmen, G. Skardal, R. Apelland, T. Borgen, M. Forfang, E. Baak, T. Dickstein, K. Olsen, I. Stachurski, D. Juszczyk, Z. Stankala, S. Gilewski, W. Sinkiewicz, W. Kasztelowicz, P. Gabryel, J. Kardaszewicz, P. Lazorko-Piega, M. Bellwon, J. Mosakowska, K. Rynkiewicz, A. Olczyk, S. Pagorek, M. Bartlinski, R. Borej, G. Tarchalski, J. Bartkowiak, R. Sosnowska-Pasiarska, B. Wozakowska-Kaplon, B. Krzeminski, A. Bury, K. Grzegorzko, A. Mirek-Bryniarska, E. Nessler, J. Zabojszcz, M. Broncel, M. Poliwczak, A. Retwinski, A. Soska, K. Grajek, S. Straburzynska-Migaj, E. Kuzniar, J. Rzeszuto, T. Bednarczyk, G. Ruszkowski, P. Piasecka-Krysiak, E. Zambrzycki, J. Nowak, T. Szelemej, R. Balsam, P. Folga, A. Kaplon-Cieslicka, A. Kowalewski, S. Mamcarz, A. Marchel, M. Opolski, G. Welnicki, M. Jankowska, E. Nowak, J. Nowalany-Kozielska, E. Rozentryt, P. Zembala, M. Kleinrok, A. Prokop-Lewicka, G. Kudlinska, B. Radoi, M. Macarie, C. Vinereanu, D. Capalneanu, R. Giuca, A. Ionescu, D.D. Nechita, E. Datcu, M. Istrate, C. Vladoianu, M. Christodorescu, R. Salguero, R. Blanco, V.M. Lavilla, M.A. Comin-Colet, J. Cantillo, D. Bernal, J. del Prado, J.M. Pita, A. Aguero, J. Jimenez, J.F. Calvo, F. Gonzalez, R. Molina, B. Luengos, D. Lostal, C. Bonet, L. Gonzalez, P. Soriano, F. Campos, M.J. Karlstrom, P. Nyrinder, I. Olsson, B. Pettersson, T. Stenberg, A. Lindmark, K. Asserlund, B. Heart Failure Association of the European Society of Cardiology (HFA)

Abstract

AimsThe ESC-HF Pilot survey was aimed to describe clinical epidemiology and 1-year outcomes of outpatients and inpatients with heart failure (HF). The pilot phase was also specifically aimed at validating structure, performance, and quality of the data set for continuing the survey into a permanent Registry.MethodsThe ESC-HF Pilot study is a prospective, multicentre, observational survey conducted in 136 Cardiology Centres in 12 European countries selected to represent the different health systems across Europe. All outpatients with HF and patients admitted for acute HF on 1 day per week for eight consecutive months were included. From October 2009 to May 2010, 5118 patients were included: 1892 (37%) admitted for acute HF and 3226 (63%) patients with chronic HF. The all-cause mortality rate at 1 year was 17.4% in acute HF and 7.2% in chronic stable HF. One-year hospitalization rates were 43.9% and 31.9%, respectively, in hospitalized acute and chronic HF patients. Major regional differences in 1-year mortality were observed that could be explained by differences in characteristics and treatment of the patients.ConclusionThe ESC-HF Pilot survey confirmed that acute HF is still associated with a very poor medium-term prognosis, while the widespread adoption of evidence-based treatments in patients with chronic HF seems to have improved their outcome profile. Differences across countries may be due to different local medical practice as well to differences in healthcare systems. This pilot study also offered the opportunity to refine the organizational structure for a long-term extended European network. © 2013 The Author.

Published
2013

167. Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study

Author

Weimer, Le, Floridia, M., Bucciardini, R., Baroncelli, S., C M, Galluzzo, M F, Pirillo, Fragola, V., Donnini, S., Mirra, M., Di Gregorio, M., Lucattini, S., Fucili, L., Angarano, G., Ladisa, N., Volpe, A., Vullo, V., D Ettorre, G., Ceccarelli, G., Andreoni, M., Sarmati, L., Delle Rose, D., Tozzi, V., Petrosillo, N., Bellagamba, R., Libertone, R., Cicalini, S., Sighinolfi, L., Daniela Segala, Armignacco, O., Preziosi, R., Ferrari, C., Degli Antoni, A., Cavalli, A., Parruti, G., Sozio, F., Cosentino, L., Vivarelli, A., P E, Manconi, Ort, F., M L, Di Martino, Viale, P., Verrucchi, G., Tedeschi, S., M S, Mura, Mannazzu, M., Cattari, G., Tavio, M., Del Gobbo, R., Mataloni Paggi, A., Giacometti, A., Cirioni, O., Marchionni, E., Silvestri, C., Sebastianelli, S., Brescini, L., Baldelli, F., Guaraldi, Giovanni, Maria Giulia Bernardini, Stentarelli, Chiara, and Beghetto, Barbara

Subjects
maraviroc, HIV infection, raltegravir, NO
Published
2013

170. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Author

Parving, Hh, Brenner, Bm, Mcmurray, Jj, de Zeeuw, D, Haffner, Sm, Solomon, Sd, Chaturvedi, N, Persson, F, Desai, As, Nicolaides, M, Richard, A, Xiang, Z, Brunel, P, Pfeffer, Ma, Viberti, G, Lachin, Jm, Zinman, B, Pedersen, Tr, Villamil, As, Juncos, L, Prager, R, Verpooten, G, Zanella, Mt, Leiter, L, Pan, C, Wang, H, Botero, R, Cifkova, R, Christiansen, Js, Groop, Ph, Marre, M, Haller, H, Nickenig, G, Siamopoulos, K, Gero, L, Maggioni, A, Remuzzi, G, Katayama, Ss, Kim, Sg, Petrulioniene, Z, Lok, D, Kooy, A, Jorde, R, Medina, F, Polonia, J, Wong, Ks, Dukat, A, Rayner, Bl, Ruilope, L, Weiss, L, Wuethrich, R, Sheu, W, Sritara, P, Comlekci, A, Bilous, R, Toto, R, Jamerson, K, Carillo, E, Orias, M, Kuschnir, E, Rusculleda, M, Garcia, S, Farias, E, Lema, L, Hominal, M, Montaña, O, Sala, J, Diaz, M, Piskorz, D, Vita, N, Litwak, L, Sinay, I, Marin, M, Massari, P, Majul, C, Aizemberg, D, Azize, Gm, Bartolacci, I, Reboredo, A, Vico, M, Milesi, R, Sessa, H, Wassermann, A, Margulis, F, Zangroniz, P, Watschinger, B, Toplak, H, Paulweber, B, Drexel, H, Francesconi, C, Foeger, B, Mayer, G, Braun, Rk, Brath, H, Gaal, Lv, Niepen, Pv, Persu, A, Vercammen, C, Vriese, Ad, Coucke, F, Mathieu, C, Fery, F, Treille, S, Meeus, G, Acker, Kv, Scheen, A, Tits, J, Ruige, J, Krzesinski, Jm, Hollanders, G, Liénart, F, Dendale, P, Quinonez, M, Arnouts, P, Vanuytsel, J, Zanella, M, Mion D., Jr, Forti, A, Almeida, F, Cunha, R, de Paula RB, Brandao, A, Rocha, J, Krieger, E, Feitosa, G, Saraiva, J, Martin, J, Hissa, Mn, Schmid, H, Felicio, J, Sgarbi, J, Oigman, W, Bowering, K, Garceau, C, Berlingieri, Jc, Weisnagel, Sj, Hardin, P, Powell, C, Turcot, R, Muirhead, N, Aronson, R, Barima, Yt, Steele, Aw, Pandey, S, Woo, V, Cha, J, Dattani, D, Godin, C, Gupta, M, Saunders, K, Tellier, G, Ting, R, Tobe, S, Chouinard, G, Schlosser, R, Khandwala, H, Ekoe, Jm, Harris, Sb, Pichette, V, Lachance, P, Ooi, Tc, Tildesley, H, Barrett, B, Cournoyer, S, Lu, J, Zhang, H, Liu, X, Yan, S, Qi, X, Li, Q, Li, H, Lv, X, Yang, J, Sun, N, Xia, W, Wang, N, Tong, N, Mei, C, Gu, S, Zhang, J, Chen, X, Li, L, Su, B, Wang, L, Qiu, M, Wu, X, Liu, Z, Jia, W, Xu, G, Dong, J, Zhu, D, Zhang, M, Yan, J, Liu, B, Chen, J, Fu, J, Yan, L, Zhan, X, Zhong, L, Yang, T, Ma, J, Xu, M, Xu, X, Shi, B, Ji, Q, Zhong, H, He, R, Yuan, Z, Zhou, Z, Lin, H, Yang, W, Ke, Y, Hong, T, Franco, C, Casas, L, Triana, A, Jaramillo, C, Hernandez, E, Barrera, C, Blanco, D, Stipal, R, Widimsky, P, Dohnalova, L, Komroskova, M, Kvapil, M, Belobradkova, J, Tesar, V, Vodnansky, P, Kocourkova, B, Lervang, Hh, Perrild, H, Rossing, P, Oestergaard, O, Juhl, H, Thorsteinsson, B, Snorgaard, O, Urhammer, S, Egstrup, K, Tikkanen, T, Helin, K, Rinne, J, Lahtela, J, Strand, J, Valtonen, E, Saari, M, Kananen, K, Savela, K, Blacher, J, Aldigier, Jc, Zaoui, P, Fauvel, Jp, Gouet, D, Valensi, Pe, Charpentier, G, Marechaud, R, Penfornis, A, Ovize, M, Kovalchuck, Aa, Dellanna, F, Schoen, N, Groeschel, W, Eickhoff, F, Hanefeld, M, Merke, J, Rambausek, M, Zimmermann, U, Stuetz, W, Vosskuehler, A, Hevendehl, G, Schax, U, Lehmann, G, Haack, A, Hilgenberg, J, Klausmann, G, Adelberger, V, Gessner, S, Fiesselmann, A, Oerter, E, Hohenstatt, T, Groeschel, A, Behnke, T, Sisting, Rt, Schoch, D, Bieler, T, Schleyer, S, Altes, U, Klepzig, C, Rudofsky, G, Mueller, G, Burkhardt, F, Reschke, K, Senftleber, I, Wiesweg, Ck, Herrmann, Hj, Brandstetter, R, Segner, A, Schmitt, H, Rippert, R, Goebel, R, Schreibmueller, F, Pencz, I, Ott, P, Migdalis, I, Pappas, S, Pagkalos, E, Yalouris, A, Tsapas, A, Maltezos, E, Tentolouris, N, Papadakis, I, Ioannidis, G, Goumenos, D, Corona, V, Gonzalez, R, Haase, F, Monterroso, V, Sánchez, V, Turcios, E, Wyss, F, Arango, Jl, Bako, B, Deak, L, Dömötör, E, Dudas, M, Fulop, T, Kiss, I, Koranyi, L, Lengyel, Z, Nyirati, G, Oroszlan, T, Aniko, S, Vörös, P, Kapocsi, J, Wittmann, I, Paragh, G, Abraham, G, Tandon, N, Thomas, N, Mohan, V, Sahay, R, Sethi, B, Rao, V, Kumar, S, Chowdhury, S, Dharmalingam, M, Seshiah, V, Bantwal, G, Viswanathan, V, Yajnik, C, Adhikari, P, Krishnan, U, Varthakavi, P, Hiremath, J, Bhattacharyya, A, Dani, S, Modi, Kk, Glorioso, N, Morosetti, M, Veglio, Franco, Perticone, F, Dotta, F, Quarello, F, Sesti, G, Aiello, A, D'Ospina, A, Giordano, C, Novo, S, Santoro, A, Ferri, C, Capuano, V, Trimarco, B, Tonolo, G, Villa, G, De Pellegrin, A, Zanette, G, Federici, M, Aucello, G, Piatti, P, Vinciguerra, A, Mannarino, E, Taddei, S, Filetti, S, Grandaliano, G, Marchionni, N, Lambiase, C, Locatelli, F, Scanferla, F, Lembo, G, Leotta, S, Mos, L, Calatola, P, Fogari, R, David, S, Pedrinelli, R, Pignone, Am, Cozzolino, D, Bevilacqua, Mt, Catena, C, Del Prato, S, Cerasola, G, Frontoni, S, Falcone, C, Porta, A, Bonora, E, Cocchi, R, Fucili, A, Frisinghelli, A, Volpe, M, Carugo, S, Gambardella, S, Spagnuolo, V, Maglia, G, D'Angelo, Ar, Corsi, A, Limone, Pp, Guarnieri, A, Ghigo, Ezio, Ronchi, E, Ravera, M, Scioli, Ga, Sekiguchi, M, Aoki, S, Ogawa, Y, Seino, H, Onishi, Y, Tojo, A, Narimiya, M, Iwaita, Y, Takeda, H, Shimizu, H, Yamada, T, Kojima, S, Zushi, S, Kaneko, S, Matsumoto, A, Kajiyama, S, Fujita, H, Shikata, K, Tone, A, Matsubayashi, S, Tanaka, S, Sekigami, T, Tatsukawa, Y, Abe, N, Kawahara, K, Kasahara, H, Maeda, Y, Suzuki, Y, Okamoto, H, Tachi, K, Yamada, K, Uzu, T, Itou, T, Fukui, T, Kim, S, Kim, Y, Cho, W, Kwak, I, Chae, D, Oh, H, Ha, S, Shin, Y, Cha, D, Kang, S, Lim, C, Song, J, Kwon, Y, Badariene, J, Labutiniene, Ip, Zabuliene, L, Poteliuniene, V, Miglinas, M, van den Meiracker AH, Gregoor, Pj, Luik, Aj, van Loon BJ, Feenstra, Hj, Kaasjager, Ha, Viergever, Pp, Woittiez, Aj, van Bemmel, T, Lieverse, Ag, Simsek, S, Gaillard, Ca, van der Zwaan, C, Lok, Dj, Spiering, W, Nierop, Pr, Baggen, Mg, Leendert, Rj, de Jong, A, Leurs, Pb, Vincent, Hh, Wins, Eh, Voors, Aa, Ronner, E, Heeg, Je, van Hal JM, Boermans, T, Feis, Wl, Mostard, G, Bakker, Rc, Dunselman, Ph, Skeie, S, Istad, H, Skjelvan, G, Gronert, J, Tomala, T, Gudnason, S, Torvik, Dt, Risberg, K, Abedini, S, Cabrera, W, Medina, B, Herrada, B, Saavedra, A, Polonia, Dj, Providencia, Dl, Carvalho, D, Vasconcelos, Mp, da Silva GF, Branco, P, Gil, Dv, da Costa AG, da Silva PM, Arez, L, Martins, L, Birne, R, Dzuponova, J, Surovcikova, M, Culak, J, Filipova, S, Andre, I, Stevlik, J, Uhliar, R, Fabryova, L, Benacka, J, Koleny, D, Szentivanyi, M, Spisak, V, Pella, D, Pastrnakova, E, Martinka, E, Chua, T, Lau, T, Ng, Tg, Yeoh, Ly, Bhana, Sa, Rayner, B, Wellmann, H, Amod, A, Ranjith, N, Ahmed, F, Rheeder, P, Makan, H, Naicker, P, Podgorski, G, De Teresa, E, Olivan, J, Fernandez, Vl, Povedano, St, Terns, M, Ricart, W, Gonzalez, Jm, Fernandez, P, Parreño Lde, T, Redon, J, Parra, J, Calvo, C, Lopez, I, Puig, Jg, Calle, A, Garcia, Jc, Lopez, Jm, Jimenez, Ml, Fraile, B, Perez, Js, Nadal, Jj, Guija, E, Calviño, J, Barrios, V, Iglesias, Jn, Armario, P, Garcia, M, Aranda, P, Brotons, C, Gomez, P, Catelao, Am, Cusachs, Ar, Sarro, M, Martinez, V, dell Valle MH, Trias, F, Comas, A, Salvador, N, Martinez, F, Hernandez, F, Martinez, J, Mateos, C, Peral, Jl, Tolosana, J, Sobrino, J, Isart, J, Vizcaino, J, Vega, Ff, Zamorano, Jl, Bacariza, M, Soubriet, A, Fernández Cruz, A, Querejeta, R, Leira, Vm, Iglesias, Fe, Ibrik, O, Martin, D, Nanclares, Ms, Mediavilla, Jd, Galceran, Jm, Lopez, A, Muros, T, Pascual, J, Casalla, F, Tornero, F, Fernandez, G, Pettersson, P, Olsen, H, Franke, F, Stroembom, U, Furuland, H, Larnefelt, H, Allemann, Y, Krapf, R, Gerber, P, Munger, R, Hayoz, D, Graf, Hj, Burnier, M, Petrillo, A, Batt, R, Constam, En, Moccetti, T, Bianda, T, Rickli, H, Bulliard, C, Wu, Kd, Lin, Sh, Wu, Cj, Sheu, Wh, Su, Sl, Chen, Sc, Chou, Cw, Lee, Ct, Yang, Tc, Chen, Hc, Sukonthasarn, A, Sriratanasathavorn, C, Eiam Ong, S, Supasyndh, O, Chanchairujira, T, Kitiyakara, C, Arici, M, Usalan, C, Guneri, S, Koc, M, Kalender, B, Ates, K, Gurgun, C, Araz, M, Demirbas, B, Biernacki, W, Calvert, J, Eavis, P, Kerrane, J, Litchfield, J, Middleton, A, Roberts, J, Simpson, H, Charles, H, Jardine, A, Fisher, M, Banerjee, D, Gallen, I, Gnudi, L, Harvey, J, O'Hare, P, Vora, J, Winocour, P, Soran, H, Browne, D, Darko, D, Mancebo, Jg, de Roa ER, Antepara, N, Carrillo, E, Berrizbeitia, M, Guevara, L, Pernalete, N, Ontiveros, C, Zigrang, W, Blakney, E, Rosenblit, P, Weinstein, R, Klaff, L, Lipetz, R, Busick, E, Tung, P, Cooperman, M, Michael, S, Sun, Ch, Hart, T, Maddux, A, Bowden, R, East, C, Arakaki, R, Villafuerte, B, Mamish, Z, Mendez, R, Connery, L, Nour, K, Wynne, A, Busch, R, Zamora, B, Sachson, R, Prasad, J, Lasala, G, Smith, M, Fitz Patrick, D, Ruiz Rivera, L, Barranco, E, Solomon, R, Woolley, A, Brown, C, Freedman, Z, Schmidt, S, Pollock, J, Ruddy, M, Kopyt, Np, Bazzi, A, Horowitz, B, Feng, W, Wahl, T, Duprez, D, Gilbert, J, Steigerwalt, S, Jacqmein, J, Gorton, S, 3rd, Allison J., Pino, J, Lock, J, Leimbach, W, Anderson, J, Beacom, M, Craig, W, Gorson, D, Kerstein, H, Segal, S, Downey, H, Ledger, G, Mcgill, J, Gabriel, J, Nolen, T, Levinson, L, Williams, T, Levenson, D, Lerman, S, Minehart, C, Agarwal, N, Verma, S, Valitutto, M, Demetry, K, Mersey, J, Koeper, D, Fanti, P, Eng, G, Grimm, R, Fagan, T, Bajaj, M, Katz, L, Portnay, G, Altschuller, A, Desai, V, Bilazarian, S, Ipp, E, Rodelas, R, Burstein, D, Berg, J, Velez, J, Lund, R, Rekhi, A, Martin, E, Robertson, D, Singh, N, Narayan, P, Moustafa, M, Lanier, D, Seidner, M, Phillips, A, Vaughters, B, Sprague, A, Swartz, S, Lopez, R, Kumar, J, Bressler, P, Sadler, L, Wise, J, Kilbane, A., and Groningen Kidney Center (GKC)

Subjects
Male, Hyperkalemia, CARDIOVASCULAR MORTALITY, BLOOD-PRESSURE, Angiotensin-Converting Enzyme Inhibitors, Type 2 diabetes, GLOMERULAR-FILTRATION-RATE, DOUBLE-BLIND, chemistry.chemical_compound, Fumarates, cardiovascular disease, Renin, Treatment Failure, Settore MED/49 - Scienze Tecniche Dietetiche Applicate, 610 Medicine & health, diabetes, Medicine (all), Hazard ratio, aliskiren, diabete, trial clinico, Liter, General Medicine, Middle Aged, hypertension, Cardiovascular Diseases, Combination, HEART-FAILURE, Drug Therapy, Combination, Female, Kidney Diseases, type 2 diabetes, medicine.symptom, Type 2, medicine.medical_specialty, Patient Dropouts, Urology, Hypokalemia, Aliskiren, chronic kidney disease, Placebo, Angiotensin Receptor Antagonists, LEFT-VENTRICULAR DYSFUNCTION, Drug Therapy, Double-Blind Method, Diabetes Mellitus, medicine, Humans, CONVERTING-ENZYME INHIBITORS, Antihypertensive Agents, Aged, Amides, Diabetes Mellitus, Type 2, Follow-Up Studies, business.industry, medicine.disease, Confidence interval, Surgery, Blood pressure, MYOCARDIAL-INFARCTION, chemistry, SYSTOLIC DYSFUNCTION, FOLLOW-UP, business
Abstract

BACKGROUND This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P = 0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, = 6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P CONCLUSIONS The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.)

Published
2012
Full Text
View/download PDF

171. La cría del cabrito y su uso culinario en la Argentina

Author

Paez Lama, Sebastián Antonio, Egea, Angela Vanina, Grilli, Diego Javier, Fucili, Mercedes, Guevara, Juan Carlos, Paez, Jesus, and Allegretti, Liliana Inés

Subjects
purl.org/becyt/ford/4.2 [https], CIENCIAS AGRÍCOLAS, Ganadería, Producción Animal y Lechería, purl.org/becyt/ford/4 [https], Sin Palabras Clave
Abstract

La población de ganado caprino en Latinoamérica se estima en unos 34,5 millones de cabezas, representando el 4 % de las existencias mundiales. En el continente americano, los países con mayor cantidad son Brasil, México y Argentina que se ubica en tercer lugar con alrededor de 4,2 millones de caprinos. Fil: Paez Lama, Sebastián Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Egea, Angela Vanina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Grilli, Diego Javier. Universidad Nacional de Cuyo; Argentina Fil: Fucili, Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Guevara, Juan Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Paez Jesus. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina Fil: Allegretti, Liliana Inés. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Provincia de Mendoza. Instituto Argentino de Investigaciones de las Zonas Áridas. Universidad Nacional de Cuyo. Instituto Argentino de Investigaciones de las Zonas Áridas; Argentina

Published
2011

175. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Author

Kondili, L., primary, Weimer, L.E., additional, Mallano, A., additional, Fucili, L., additional, Massella, M., additional, Vinci, M., additional, Borgia, G., additional, Brunetto, M., additional, Surace, L., additional, Gaeta, G.B., additional, Chemello, L., additional, Andreone, P., additional, Raimondo, G., additional, Filomia, R., additional, Persico, M., additional, Puoti, M., additional, Rumi, M.G., additional, Benedetti, A., additional, Fargion, S., additional, Ieluzzi, D., additional, Nardone, G., additional, Giuseppe, F., additional, Ciancio, A., additional, Taliani, G., additional, Biliotti, E., additional, Madonia, S., additional, Stagno, B., additional, Alberti, A., additional, Massari, M., additional, Rosina, F., additional, Mazzella, G., additional, Di Leo, A., additional, Iannone, A., additional, Ferrari, C., additional, Orlandini, A., additional, Monti, M., additional, Santantonio, T.A., additional, Chessa, L., additional, Erne, E.M., additional, Coppola, C., additional, Andreoni, M., additional, Baldelli, F., additional, Mondelli, M., additional, Blanc, P., additional, Gasbarrini, A., additional, Verucchi, G., additional, Colombo, M., additional, Borghi, M., additional, Craxì, A., additional, Petta, S., additional, Villa, E., additional, Patti, O., additional, Russo, F.P., additional, Strazzabosco, M., additional, Vella, S., additional, and Zignego, A.L., additional

Published
2016
Full Text
View/download PDF

179. ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI

Author

Bucciardini, R., Floridia, M., Weimer, Le, Fragola, V., Massella, M., Baroncelli, S., Pirillo, Mf, Galluzzo, Cm, Donnini, S., Mirra, M., Di Gregorio, M., Lucattini, S., Fucili, L., Baldelli, F., Francisci, D., Martinelli, L., Bastianelli, S., Pastore, G., Ladisa, N., Volpe, A., Vullo, V., D Ettore, G., Ceccarelli, G., Andreoni, M., Sarmati, L., Delle Rose, D., Montano, M., Tozzi, V., Libertone, R., Pucillo, L., Narciso, P., Bellagamba, R., Tommasi, C., Petrosillo, N., Cicalini, S., Sighinolfi, L., Daniela Segala, Armignacco, O., Preziosi, R., Ferrari, C., Antoni, Ad, Cavalli, A., Parruti, G., Sozio, F., Cosentino, L., Dionisio, D., Vivarelli, A., Manconi, Pe, Ortu, F., Di Martino, Ml, Chiodo, F., Biagelti, C., Borderi, M., Boni, P., Del Gobbo, R., Paggi, Am, Silvestri, C., Scalise, G., Giacometti, A., Cirioni, O., Mura, Ms, Mannazzu, M., Coinu, G., Bellissima, P., Bonfante, S., Neri, D., Guaraldi, G., and Beghetto, B.

Subjects
antiretroviral therapy, HIV, COHORT STUDY, NO
Published
2009

182. HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Author

M. Puoti, M. Borghi, Alfredo Alberti, Marco Massari, Silvia Fargion, B. Stagno, L Surace, Teresa Santantonio, Roberto Filomia, L. Fucili, Floriano Rosina, Le Weimer, Carlo Ferrari, Em Erne, Carmine Coppola, S. Madonia, A. Di Leo, Alessia Ciancio, Giovanni Raimondo, Monica Monti, Maurizia Rossana Brunetto, O. Patti, Andrea Iannone, G. B. Gaeta, Salvatore Petta, G. Nardone, Pierluigi Blanc, Fp Russo, M. Rumi, María Isabel Colombo, Gabriella Verucchi, M. Andreoni, A. Mallano, Stefano Vella, Maria Cristina Vinci, F. Baldelli, Antonio Benedetti, Erica Villa, Marcello Persico, Liliana Chemello, Loreta A. Kondili, F Giuseppe, Al Zignego, P. Andreone, Gloria Taliani, Luchino Chessa, M. Strazzabosco, Antonio Gasbarrini, Giuseppe Mazzella, Mario U. Mondelli, Elisa Biliotti, Alessandra Orlandini, M. Massella, D. Ieluzzi, Antonio Craxì, and Guglielmo Borgia

Subjects
030203 arthritis & rheumatology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, Internal medicine, Mixed cryoglobulinemia, Medicine, 030211 gastroenterology & hepatology, business, Cohort study
Published
2016
Full Text
View/download PDF

184. Notas para el análisis de los perfiles y trayectorias políticas. El estudio de los elencos dirigentes del una provincia de interior argentino (Mendoza, 1852-1900).

Author

Valeria Fucili, Eliana

Abstract

Copyright of Historia y Sociedad (01218417) is the property of Universidad Nacional de Colombia, Facultad de Ciencias Humanas y Economicas and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

185. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review

Author

Roberto Ferrari, Donato Mele, Alessandro Fucili, Claudio Ceconi, Giordano Cicchitelli, and Elisa Merli

Subjects
medicine.medical_specialty, Cardiotonic Agents, Ischemia, Myocardial Ischemia, Pharmacology, General Biochemistry, Genetics and Molecular Biology, NO, Levocarnitine, Coronary artery disease, History and Philosophy of Science, Carnitine, medicine, Humans, Myocardial infarction, Ventricular remodeling, business.industry, General Neuroscience, Valproic Acid, Hypoxia (medical), medicine.disease, Surgery, Liver, Cardiovascular Diseases, Heart failure, Kidney Failure, Chronic, medicine.symptom, business, medicine.drug
Abstract

Several experimental studies have shown that levocarnitine reduces myocardial injury after ischemia and reperfusion by counteracting the toxic effect of high levels of free fatty acids, which occur in ischemia, and by improving carbohydrate metabolism. In addition to increasing the rate of fatty acid transport into mitochondria, levocarnitine reduces the intramitochondrial ratio of acetyl-CoA to free CoA, thus stimulating the activity of pyruvate dehydrogenase and increasing the oxidation of pyruvate. Supplementation of the myocardium with levocarnitine results in an increased tissue carnitine content, a prevention of the loss of high-energy phosphate stores, ischemic injury, and improved heart recovery on reperfusion. Clinically, levocarnitine has been shown to have anti-ischemic properties. In small short-term studies, levocarnitine acts as an antianginal agent that reduces ST segment depression and left ventricular end-diastolic pressure. These short-term studies also show that levocarnitine releases the lactate of coronary artery disease patients subjected to either exercise testing or atrial pacing. These cardioprotective effects have been confirmed during aortocoronary bypass grafting and acute myocardial infarction. In a randomized multicenter trial performed on 472 patients, levocarnitine treatment (9 g/day by intravenous infusion for 5 initial days and 6 g/day orally for the next 12 months), when initiated early after acute myocardial infarction, attenuated left ventricular dilatation and prevented ventricular remodeling. In treated patients, there was a trend towards a reduction in the combined incidence of death and CHF after discharge. Levocarnitine could improve ischemia and reperfusion by (1) preventing the accumulation of long-chain acyl-CoA, which facilitates the production of free radicals by damaged mitochondria; (2) improving repair mechanisms for oxidative-induced damage to membrane phospholipids; (3) inhibiting malignancy arrhythmias because of accumulation within the myocardium of long-chain acyl-CoA; and (4) reducing the ischemia-induced apoptosis and the consequent remodeling of the left ventricle. Propionyl-L-carnitine is a carnitine derivative that has a high affinity for muscular carnitine transferase, and it increases cellular carnitine content, thereby allowing free fatty acid transport into the mitochondria. Moreover, propionyl-L-carnitine stimulates a better efficiency of the Krebs cycle during hypoxia by providing it with a very easily usable substrate, propionate, which is rapidly transformed into succinate without energy consumption (anaplerotic pathway). Alone, propionate cannot be administered to patients in view of its toxicity. The results of phase-2 studies in chronic heart failure patients showed that long-term oral treatment with propionyl-L-carnitine improves maximum exercise duration and maximum oxygen consumption over placebo and indicated a specific propionyl-L-carnitine effect on peripheral muscle metabolism. A multicenter trial on 537 patients showed that propionyl-L-carnitine improves exercise capacity in patients with heart failure, but preserved cardiac function.

Published
2004

186. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure

Author

Olga Soukhomovskaia, Patrizia Malagutti, Anna Maria Bugli, Gloria Francolini, Roberto Ferrari, Marco Valgimigli, Matteo G. Della Porta, Gianluigi Castoldi, Letizia Zenone Bragotti, Gian Matteo Rigolin, Alessandro Fucili, and Endri Mauro

Subjects
Adult, Male, Vascular Endothelial Growth Factor A, medicine.medical_specialty, Stromal cell, Endothelium, Angiogenesis, Cells, CD34, Antigens, CD34, Colony-Forming Units Assay, chemistry.chemical_compound, Physiology (medical), Internal medicine, Granulocyte Colony-Stimulating Factor, Natriuretic Peptide, Brain, medicine, Humans, Receptors, Tumor Necrosis Factor, Type II, Endothelial dysfunction, Progenitor cell, Aged, Aged, 80 and over, Heart Failure, business.industry, Tumor Necrosis Factor-alpha, Interleukins, Mesenchymal Stem Cells, Middle Aged, medicine.disease, Hematopoietic Stem Cells, Vascular Endothelial Growth Factor Receptor-2, Chemokine CXCL12, Vascular endothelial growth factor, medicine.anatomical_structure, Endocrinology, chemistry, Receptors, Tumor Necrosis Factor, Type I, Heart failure, Tumor necrosis factor alpha, Female, Endothelium, Vascular, Cardiology and Cardiovascular Medicine, business, Chemokines, CXC, Biomarkers
Abstract

Background— Peripheral blood CD34 + cells and circulating endothelial progenitor cells (EPCs) increase in myocardial infarction and vascular injuries as a reflection of endothelial damage. Despite the occurrence of endothelial dysfunction in heart failure (HF), no data are available on EPC mobilization in this setting. We investigated the pattern of CD34 + cells and EPC mobilization during HF and their correlation with the severity and origin of the disease. Methods and Results— Peripheral blood CD34 + cells (n=91) and EPCs (n=41), assessed both as CD34 + cells coexpressing AC133 and vascular endothelial growth factor (VEGF) receptor-2 and as endothelial colony-forming units, were studied in HF patients (mean age 67±11 years) and 45 gender- and age-matched controls. Tumor necrosis factor-α (TNF-α) and its receptors (sTNFR-1 and sTNFR-2), VEGF, stromal derived factor-1 (SDF-1), granulocyte-colony stimulating factor (G-CSF), and B-type natriuretic peptide were also measured. CD34 + cells, EPCs, TNF-α and receptors, VEGF, SDF-1, and B-type natriuretic peptide were increased in HF. CD34 + cells and EPCs were inversely related to functional class and to TNF-α, being decreased in New York Heart Association class IV compared with class I and II and controls. No role was found for the origin of the disease. Conclusions— CD34 + cells and EPC mobilization occurs in HF and shows a biphasic response, with elevation and depression in the early and advanced phases, respectively. This could be related to the myelosuppressive role of TNF-α.

Published
2004

187. CARDIOLOGIA MOLECOLARE. Nuove frontiere diagnostiche e terapeutiche

Author

Vatta, M., Nanni, L., Lanfranchi, G., Cargnoni, A., Merli, E., Cicchitelli, G., Ceconi, Claudio, Fucili, A., Ferrari, Roberto, Agnolotti, L., Ferrara, N., Grassi, G., Zacchigna, S., Giacca, M., Angelini, A., Castellani, C., and Thiene, G.

Published
2004

194. Contribution of the surface contamination of uranium materials on the quantitative analysis results by electron probe microbeam analysis

Author

Catherine Fucili, Olivier Bonino, O. Dugne, Cécile Fournier, and Claude Merlet

Subjects
chemistry.chemical_compound, Surface coating, Auger electron spectroscopy, Microprobe, Materials science, chemistry, Analytical chemistry, Oxide, chemistry.chemical_element, Electron microprobe, Uranium, Electron spectroscopy, Microanalysis
Abstract

The first part of this paper is devoted to the study of contaminated surface of the uranium materials U, UFe2 and U6Fe a few hours after the preparation. These oxidation conditions are selected with the aim to reproduce the same contamination surfaces that occurred in microprobe analytical conditions. The surface characterization techniques are SIMS and Auger spectroscopy. The contaminated surfaces are described. They are made of successive layers: a carbon layer, one oxidized iron layer followed by an iron depletion layer (only in UFe2 and U6Fe), and a ternary oxide layer (U-Fe-O for UFe2 et U6Fe and UO2+x for the uranium). The second part of this paper is devoted to estimating errors caused by surface contamination during quantitative analysis. EPMA-WDS is used to make the estimation. The analyses were carried out with a CAMECA SX100 and the simulation with the X-Film software.

Published
2000
Full Text
View/download PDF

198. FRI-181 - HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study

Author

Kondili, L., Weimer, L.E., Mallano, A., Fucili, L., Massella, M., Vinci, M., Borgia, G., Brunetto, M., Surace, L., Gaeta, G.B., Chemello, L., Andreone, P., Raimondo, G., Filomia, R., Persico, M., Puoti, M., Rumi, M.G., Benedetti, A., Fargion, S., Ieluzzi, D., Nardone, G., Giuseppe, F., Ciancio, A., Taliani, G., Biliotti, E., Madonia, S., Stagno, B., Alberti, A., Massari, M., Rosina, F., Mazzella, G., Di Leo, A., Iannone, A., Ferrari, C., Orlandini, A., Monti, M., Santantonio, T.A., Chessa, L., Erne, E.M., Coppola, C., Andreoni, M., Baldelli, F., Mondelli, M., Blanc, P., Gasbarrini, A., Verucchi, G., Colombo, M., Borghi, M., Craxì, A., Petta, S., Villa, E., Patti, O., Russo, F.P., Strazzabosco, M., Vella, S., and Zignego, A.L.

Published
2016
Full Text
View/download PDF

199. Understanding the Pathophysiology of IBS

Author

Barbara, Giovanni, primary, Dolci, Marco, additional, Cremon, Cesare, additional, Barbaro, Maria Raffaella, additional, Bellacosa, Lara, additional, Fucili, Anita, additional, and Stanghellini, Vincenzo, additional

Published
2013
Full Text
View/download PDF

200. Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study

Author

Beghé, Bianca, primary, Verduri, Alessia, additional, Bottazzi, Barbara, additional, Stendardo, Mariarita, additional, Fucili, Alessandro, additional, Balduzzi, Sara, additional, Leuzzi, Chiara, additional, Papi, Alberto, additional, Mantovani, Alberto, additional, Fabbri, Leonardo M., additional, Ceconi, Claudio, additional, and Boschetto, Piera, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results